BACKGROUND AND OBJECTIVES
*Mycobacterium tuberculosis*, which resides inside macrophages, has always been recognized as one of the most “successful” pathogens. Standard treatments have already been used for decades and, therefore, resistances to the first-line medicines are increasing. Additionally, poor patient compliance with stringent therapies is often pointed out as a major reason leading to treatment failure.

Antimicrobial peptides (AMPs), a promising new class of broad spectrum antibiotics, are less prone to result in pathogen resistances due to their target (cellular membranes) and rapid action. In our laboratory we search for AMPs with potent activity against mycobacteria and try to develop efficient delivery systems based on self-assembled colloidal nanocarriers. Additionally, this systems are expected to reduce peptide toxicity and enhance selective uptake on infected cells. Finally, the use of encapsulated drugs in mycobacterial therapy may help reducing drug administration schedules which would ultimately improve patient compliance.

WORK PLAN
1. Optimization of therapeutic formulations for AMPs controlled delivery.
2. In vitro and in vivo delivery of AMPs to infected macrophages; Analysis of mechanisms of therapeutic action and potential side effects.
3. Study binding, internalization mechanisms and intracellular fate of the nanocarriers (University of Oxford).
4. In vivo biodistribution of the nanocarrier (University of Groningen).
5. Study the global pharmacoeconomic impact of AMPs as new therapeutic agents to fight tuberculosis.

RESULTS
We have used encapsulated AMPs (Fig. 1) to tackle an infection promoted by *M. avium* in mouse macrophages *in vitro*. During 7 days the peptide has killed more than 99% of initial bacterial burden. The bactericidal effect has already been confirmed using infected mice *in vivo*, by applying the therapeutic formulation via the pulmonary route (Fig. 2). Currently, we are moving for more potent mycobacteria, such as *M. tuberculosis*, which shows identical susceptibility to the antimicrobial formulation.

Background:

MSc. Bioengineering / Faculty of Engineering - University of Porto / Portugal

Starting year:

2012/2013

Research team:

João Pedro Silva1; Jeremy Sousa1; António Gil Castro1; Jorge Pedroso1; Rui Appelberg1; Miguel Gama1

External collaborators:

Fernando Martínez Estrada1; Subhankar Mukhopadhyay2; Siamon Gordon2; Erik de Vries2

Supervisors:

Miguel Gama1; Rui Appelberg1; Jorge Pedroso1

1 Centre of Biological Engineering, University of Minho, Portugal
2 Life and Health Sciences Research Institute, University of Minho, Portugal
3 Institute for Molecular and Cell Biology, University of Porto, Portugal
4 University of Oxford, England
5 University of Groningen, The Netherlands

FIGURE 1
Schematic representation of the peptide nanocarrier.

FIGURE 2
Intratracheal drug delivery using a MicroSprayer® aerosolizer in mice.